MedTrace Logo

Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy

NCT04923620 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 51

Last updated 2024-02-26

No results posted yet for this study

Summary

Prospectively Investigate the effectiveness and safety of neoadjuvant cetuximab + chemotherapy (mFOLFOX6) combined with short-course radiotherapy (25Gy/5Fx) for RAS wild-type locally advanced rectal cancer

Conditions

Interventions

DRUG

cetuximab+mFOLFOX6

cetuximab 500mg/m2 d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles

RADIATION

short-course radiotherapy

25Gy/5Fx short-course radiotherapy between the forth and the fifth cycle of cetuximab+mFOLFOX6

Sponsors & Collaborators

  • Shanghai Minimally Invasive Surgery Center

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-20
Primary Completion
2024-08-31
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04923620 on ClinicalTrials.gov